文献速递银屑病与炎症性皮肤病

古塞奇尤单抗治疗儿童中重度斑块状银屑病:III期随机安慰剂对照PROTOSTAR研究结果

Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study.
PubMed 文献 · Br J Dermatol · 2025-01-01

PROTOSTAR是一项III期随机安慰剂对照研究,纳入6至<18岁中重度斑块状银屑病患者。第1部分第16周时,古塞奇尤单抗组IGA 0/1、PASI 75和PASI 90应答率均显著高于安慰剂组,安全性特征与成人一致,支持其用于儿童患者。

要点

  • 古塞奇尤单抗在第16周显著优于安慰剂,达到所有主要终点。
  • 第52周时,持续开放标签治疗中超过80%患者维持高应答。
  • 安全性特征与安慰剂相似,未发现新的安全信号。

核心结论

  • 古塞奇尤单抗在儿童中重度斑块状银屑病患者中显示出显著且具有临床意义的疗效,所有共同主要终点和主要次要终点均达到。
  • 安全性结果与安慰剂相似,并与成人已确立的安全性特征一致,未发现新的安全信号。

研究设计与样本

  • III期随机安慰剂对照研究(PROTOSTAR;NCT03451851),纳入年龄≥6至<18岁的中重度斑块状银屑病患者。
  • 第1部分(W0-W16)患者随机接受古塞奇尤单抗、安慰剂或开放标签依那西普(活性参照组);第16周后进入古塞奇尤单抗撤药/再治疗期或继续/交叉接受古塞奇尤单抗至W52。
  • 第2部分评估持续开放标签古塞奇尤单抗治疗(W0-W52)。
  • 第1部分和第2部分分别纳入92例和28例患者,分别有86%和96%持续治疗至W52。

主要发现

  • 第1部分第16周,古塞奇尤单抗组对比安慰剂组:IGA 0/1为66% vs. 16%(P < 0.001),PASI 75为76% vs. 20%(P < 0.001),PASI 90为56% vs. 16%(P < 0.01)。
  • 第1部分第16周,古塞奇尤单抗组中超过三分之一患者达到皮损完全清除:IGA 0为39% vs. 安慰剂4%(P < 0.01),PASI 100为34% vs. 安慰剂0%(P < 0.01)。
  • 第2部分第52周,古塞奇尤单抗治疗患者中IGA 0/1、PASI 75和PASI 90应答率分别为86%、93%和82%。
  • 第1部分至第16周,古塞奇尤单抗组、安慰剂组和依那西普组分别有42%、68%和58%的患者发生不良事件(AEs)。
  • 古塞奇尤单抗组AEs发生率在第1部分和第2部分至第52周相似;常见AEs包括鼻咽炎、上呼吸道感染和COVID-19;未发生严重或机会性感染。

临床怎么用

  • 研究结果支持古塞奇尤单抗用于治疗儿童中重度斑块状银屑病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No currently approved treatment for paediatric plaque psoriasis selectively targets interleukin (IL)-23. In adults, guselkumab (a selective IL-23 inhibitor that targets the p19 subunit) demonstrated substantial efficacy with a favourable safety profile in treating moderate-to-severe plaque psoriasis. OBJECTIVES: To evaluate the efficacy and safety of guselkumab in paediatric patients with moderate-to-severe plaque psoriasis (PROTOSTAR; NCT03451851). METHODS: This phase III randomized placebo-controlled study enrolled patients aged ≥ 6 to < 18 years with moderate-to-severe plaque psoriasis. In part 1 [week (W)0-W16], patients were randomized to receive guselkumab, placebo or open-label etanercept (active reference arm). At W16, part 1 patients entered a guselkumab withdrawal/retreatment period or continued/crossed over to receive guselkumab (W16-W52). Co-primary endpoints were Investigator Global Assessment (IGA) 0/1 and ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) [or U.S. Food and Drug Administration-required ≥ 90% improvement in PASI (PASI 90) co-primary endpoint] responses at W16 of part 1. Part 2 evaluated continuous open-label guselkumab treatment (W0-W52). RESULTS: Of 92 and 28 patients enrolled in parts 1 and 2, respectively, 86% and 96% continued treatment through W52. In part 1, at W16, significantly higher proportions of guselkumab-treated compared with placebo-treated patients achieved IGA 0/1 (66% vs. 16%; P < 0.001), PASI 75 (76% vs. 20%; P < 0.001) and PASI 90 (56% vs. 16%; P < 0.01). More than one-third of guselkumab-treated patients achieved clear skin [IGA 0: 39% vs. 4% placebo; 100% improvement in PASI (PASI 100): 34% vs. 0% placebo; both P < 0.01]. In part 2, at W52, 86%, 93% and 82% of guselkumab-treated patients achieved IGA 0/1, PASI 75 and PASI 90, respectively. Through W16 of part 1, 42%, 68% and 58% of guselkumab-, placebo- and etanercept-treated patients, respectively, experienced adverse events (AEs). Rates of AEs with guselkumab were similar through W52 in parts 1 and 2; common AEs included nasopharyngitis, upper respiratory tract infection and COVID-19. No serious or opportunistic infections occurred. CONCLUSIONS: Guselkumab demonstrated significant and clinically meaningful responses in paediatric patients with moderate-to-severe plaque psoriasis, and all co-primary and major secondary endpoints were met. Safety outcomes for guselkumab in paediatric patients were similar to placebo and consistent with the established profile in adults, with no new safety signals identified. These findings support the use of guselkumab to treat paediatric patients with moderate-to-severe plaque psoriasis. Worldwide, 2% to 3% of people have psoriasis. About a third of these people develop the disease before adulthood. A type of the disease called ‘plaque psoriasis’ is a chronic, inflammatory skin disease. It can be itchy and painful. A drug called ‘guselkumab’ can be used to treat adults with moderate-to-severe plaque psoriasis. In adults, guselkumab has been shown to improve plaque psoriasis, with side effects similar to those of a placebo (or ‘dummy’ drug). We wanted to find out if guselkumab is a safe and effective treatment for children and adolescents with moderate-to-severe plaque psoriasis. In study part 1, patients were randomly assigned to receive guselkumab or placebo for 16 weeks. After week 16, depending on their response to the treatment, patients were able to stop taking guselkumab, continue taking it or change from placebo to guselkumab. The goal of study part 1 was to compare the percentage of patients who achieved clear or almost clear skin with guselkumab at week 16 with the percentage of patients who achieved clear or almost clear skin with placebo at week 16. In study part 2, patients received guselkumab for up to 1 year. Ninety-two patients were enrolled in study part 1, and 28 were enrolled in study part 2. In study part 1, significantly more patients treated with guselkumab than patients given the placebo achieved clear or almost clear skin at week 16. In study part 2, more than 80% of patients had clear or almost clear skin after 1 year of guselkumab treatment. In both parts of the study, patients who took guselkumab and their families said they had an improved quality of life. In study part 1, at week 16, side effects were seen in 42% of patients who took guselkumab and in 68% of patients who took placebo. After 1 year of guselkumab treatment, the most common side effects in both parts of the study were infections that were not serious. The results suggest that guselkumab is a promising treatment for children and adolescents with moderate-to-severe plaque psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Prajapati VH, Seyger MMB, Wilsmann-Theis D, et al. Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study. Br J Dermatol. 2025. PMID: 39708367. doi:10.1093/bjd/ljae502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。